Evidence map›Paper›PMID 24780009›Full record

ArticleBiological psychiatry2014

Kappa-opioid receptor antagonism: a mechanism for treatment of relief drinking?

Markus Heilig, Jesse R Schank

Abstract readComment
PubMed Publisher
In one paragraph

Article in Biological psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Article
  3. Review
  4. Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment.Progress in neuro-psychopharmacology & biological psychiatry · 2015
    Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Markus HeiligLaboratory of Clinical and Translational Studies, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland. Electronic address: markus.heilig@mail.nih.gov.
Jesse R SchankDepartment of Physiology and Pharmacology, College of Veterinary Medicine, The University of Georgia, Athens, Georgia.

Funding

Discovery and validation of novel targets for pharmacotherapy of alcoholismZIAAA000487 · NIAAA · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · PI LOVINGER, DAVID M · 2009 to 2015
$23.6M
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AlcoholismAnimalsCentral Amygdaloid NucleusCentral Nervous System DepressantsEthanolMaleReceptors, OpioidReceptors, Opioid, kappaCentral Nervous System Depressantsdynorphin receptorEthanolReceptors, OpioidReceptors, Opioid, kappa

Identifiers

PMID24780009

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.